Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:Quinone oxidoreductase (PfNDH2)

Journal of Medicinal Chemistry

Volumn 55, Issue 5, 2012, Pages 1831-1843

  Pidathala, Chandrakala ^a   Amewu, Richard ^a   Pacorel, Bénédicte ^a   Nixon, Gemma L ^b   Gibbons, Peter ^a   Hong, W David ^a   Leung, Suet C ^a   Berry, Neil G ^a   Sharma, Raman ^b   Stocks, Paul A ^b   Srivastava, Abhishek ^b   Shone, Alison E ^b   Charoensutthivarakul, Sitthivut ^a   Taylor, Lee ^a   Berger, Olivier ^a   Mbekeani, Alison ^b   Hill, Alasdair ^b   Fisher, Nicholas E ^b   Warman, Ashley J ^b   Biagini, Giancarlo A ^b   Ward, Stephen A ^b   O'Neill, Paul M ^a   more..

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 CHLORO 3 METHYL 2 [4 [4 (TRIFLUOROMETHOXY)BENZYL]PHENYL]QUINOLIN 4 (1H)ONE; ANTIMALARIAL AGENT; BISARYL QUINOLONE; CYTOCHROME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER MICROSOME; PLASMODIUM FALCIPARUM; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIMALARIALS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ELECTRON TRANSPORT COMPLEX III; HUMANS; MALARIA; MALE; MICE; MICROSOMES, LIVER; MODELS, MOLECULAR; PARASITIC SENSITIVITY TESTS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; QUINOLONES; QUINONE REDUCTASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84858055741     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201179h     Document Type: Article

References (37)

1. Snow, R. W.; Trape, J. F.; Marsh, K. The past, present and future of childhood malaria mortality in Africa Trends Parasitol. 2001, 17 (12) 593-597
2. White, N. J. Antimalarial drug resistance J. Clin. Invest. 2004, 113 (8) 1084-1092
3. Malaria; Fact Sheet Number 94; World Health Organization: Geneva, Switzerland, 2009.
4. Burrows, J. N.; Chibale, K.; Wells, T. N. The state of the art in anti-malarial drug discovery and development Curr. Top. Med. Chem. 2011, 11 (10) 1226-1254
5. A research agenda for malaria eradication: drugs. PLoS Med. 2011, 8 (1), e1000402.
6. Biagini, G. A.; Viriyavejakul, P.; O'Neill, P, M.; Bray, P. G.; Ward, S. A. Functional characterization and target validation of alternative complex I of Plasmodium falciparum mitochondria Antimicrob. Agents Chemother. 2006, 50 (5) 1841-1851
7. Fisher, N.; Bray, P. G.; Ward, S. A.; Biagini, G. A. The malaria parasite type II NADH:quinone oxidoreductase: an alternative enzyme for an alternative lifestyle Trends Parasitol. 2007, 23 (7) 305-310
8. Fry, M.; Pudney, M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4- (4′-chlorophenyl) cyclohexyl]-3- hydroxy-1,4-naphthoquinone (566C80) Biochem. Pharmacol. 1992, 43 (7) 1545-1553
9. Fisher, N.; Warman, A. J.; Ward, S. A.; Biagini, G. A. Chapter 17 Type II NADH: quinone oxidoreductases of Plasmodium falciparum and Mycobacterium tuberculosis kinetic and high-throughput assays. Methods Enzymol. 2009, 456, 303-320.
10. Durant, J. L.; Leland, B. A.; Henry, D. R.; Nourse, J. G. Reoptimization of MDL keys for use in drug discovery J. Chem. Inf. Comput. Sci. 2002, 42 (6) 1273-1280
11. Rogers, D.; Hahn, M. Extended-connectivity fingerprints J. Chem. Inf. Model. 2010, 50 (5) 742-754
12. Willett, P. Similarity-based virtual screening using 2D fingerprints Drug Discovery Today 2006, 11 (23-24) 1046-1053
13. Geppert, H.; Vogt, M.; Bajorath, J. Current trends in ligand-based virtual screening: molecular representations, data mining methods, new application areas, and performance evaluation J. Chem. Inf. Model. 2010, 50 (2) 205-216
14. Liu, K.; Feng, J.; Young, S. S. PowerMV: A software environment for molecular viewing, descriptor generation, data analysis and hit evaluation J. Chem. Inf. Model. 2005, 45 (2) 515-522
15. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 2000, 44 (1) 235-249
16. Waring, M. J. Lipophilicity in drug discovery Exp. Opin. Drug Discovery 2010, 5 (3) 235-248
17. Hughes, J. D.; Blagg, J.; Price, D. A.; Bailey, S.; DeCrescenzo, G. A.; Devraj, R. V.; Ellsworth, E.; Fobian, Y. M.; Gibbs, M. E.; Gilles, R. W.; Greene, N.; Huang, E.; Krieger-Burke, T.; Loesel, J.; Wager, T.; Whiteley, L.; Zhang, Y. Physiochemical drug properties associated with in vivo toxicological outcomes Bioorg. Med. Chem. Lett. 2008, 18 (17) 4872-4875
18. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 2008, 51 (4) 817-834
19. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002, 45 (12) 2615-2623
20. Fray, M. J.; Bull, D. J.; Carr, C. L.; Gautier, E. C.; Mowbray, C. E.; Stobie, A. Structure-activity relationships of 1,4-dihydro-(1H,4H)-quinoxaline- 2,3-diones as N -methyl- d -aspartate (glycine site) receptor antagonists. 1. Heterocyclic substituted 5-alkyl derivatives J. Med. Chem. 2001, 44 (12) 1951-1962
21. Ishikawa, M.; Hashimoto, Y. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry J. Med. Chem. 2011, 54, 1539-1554
22. Yalkowsky, S. H.; Banerjee, S. Aqueous Solubility: Methods of Estimation for Organic Compounds; Marcel Dekker: New York, 1992.
23. Luo, F.-T.; Ravi, V. K.; Xue, C. The novel reaction of ketones with o-oxazoline-substituted anilines Tetrahedron 2006, 62, 9365-9372
24. Bueno, J. M.; Manzano, P.; García, M.; J., C.; Puente, M.; Lorenzo, A.; García, A.; Ferrer, S.; Gómez, R. M.; Fraile, M. T.; Lavander, J. L.; Fiandor, J. M.; Vidala, J.; Herreros, E.; Gargallo-Violaa, D. Potent Antimalarial 4-pyridones with improved physico-chemical properties Bioorg. Med. Chem. Lett. 2011, 21, 5214-5218
25. Bueno-Calderon, J. M.; Fiandor-Roman, J. M.; Puente-Felipe, M.; Chicharrp-Gonzalo, J.; Kusalakumari Sukamar, S. K.; Maleki, M., Phosphate ester of a 4-pyridone derivative and its use in the chemotherapy of parasitic infections. WO2010094738, 26th August 2010.
26. Cundy, K. C.; Annamalai, T.; Bu, L.; De Vera, J.; Estrela, J.; Luo, W.; Shirsat, P.; Torneros, A.; Yao, F.; Zou, J.; Barrett, R. W.; Gallop, M. A. XP13512 [(±)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys J. Pharmacol. Exp. Ther. 2004, 311 (1) 324-333
27. Hofle, G.; Bohlendorf, B.; Fecker, T.; Sasse, F.; Kunze, B. Semisynthesis and antiplasmodial activity of the quinoline alkaloid aurachin E J. Nat. Prod. 2008, 71 (11) 1967-1969
28. Miyoshi, H.; Takegami, K.; Sakamoto, K.; Mogi, T.; Iwamura, H. Characterization of the ubiquinol oxidation sites in cytochromes bo and bd from Escherichia coli using aurachin C analogues J. Biochem. 1999, 125 (1) 138-142
29. Lin, S. S.; Gross, U.; Bohne, W. Type II NADH dehydrogenase inhibitor 1-hydroxy-2-dodecyl-4(1H)quinolone leads to collapse of mitochondrial inner-membrane potential and ATP depletion in Toxoplasma gondii Eukaryotic Cell 2009, 8 (6) 877-887
30. Dong, C. K.; Patel, V.; Yang, J. C.; Dvorin, J. D.; Duraisingh, M. T.; Clardy, J.; Wirth, D. F. Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors Bioorg. Med. Chem. Lett. 2009, 19 (3) 972-975
31. Woschek, A.; Mahout, M.; Mereiter, K.; Hammerschmidt, F. Synthesis of 2-heptyl-1-hydroxy-4(1H)-quinolone-unexpected rearrangement of 4-(Alkoxycarbonyl)quinoline N-oxides to 1-(Alkoxycarbonyloxy)-4(1H)-quinolones Synthesis 2007, 10, 1517-1522
32. Zask, A.; Kaplan, J.; Verheijen, J. C.; Richard, D. J.; Curran, K.; Brooijmans, N.; Bennett, E. M.; Toral-Barza, L.; Hollander, I.; Ayral-Kaloustian, S.; Yu, K. Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors J. Med. Chem. 2009, 52 (24) 7942-7945
33. Chou, L. C.; Chen, C. T.; Lee, J. C.; Way, T. D.; Huang, C. H.; Huang, S. M.; Teng, C. M.; Yamori, T.; Wu, T. S.; Sun, C. M.; Chien, D. S.; Qian, K.; Morris-Natschke, S. L.; Lee, K. H.; Huang, L. J.; Kuo, S. C. Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumor agent J. Med. Chem. 2010, 53 (4) 1616-1626
34. Biagini, G. A.; Fisher, N.; Berry, N.; Stocks, P. A.; Meunier, B.; Williams, D. P.; Bonar-Law, R.; Bray, P. G.; Owen, A.; O'Neill, P. M.; Ward, S. A. Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex Mol. Pharmacol. 2008, 73 (5) 1347-1355
35. Peters, W.; Robinson, B. L. Malaria; Academic Press: San Diego, 1999.
36. Trager, W.; Jensen, J. B. Human malaria parasites in continuous culture Science 1976, 193 (4254) 673-675
37. Smilkstein, M.; Sriwilaijaroen, N.; Kelly, J. X.; Wilairat, P.; Riscoe, M. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening Antimicrob. Agents Chemother. 2004, 48 (5) 1803-1806